Search Results - "Thomas, Renato"

MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b by Roscigno, Giuseppina, Quintavalle, Cristina, Donnarumma, Elvira, Puoti, Ilaria, Diaz-Lagares, Angel, Iaboni, Margherita, Fiore, Danilo, Russo, Valentina, Todaro, Matilde, Romano, Giulia, Thomas, Renato, Cortino, Giuseppina, Gaggianesi, Miriam, Esteller, Manel, Croce, Carlo M, Condorelli, Gerolama

“…Cancer stem cells (CSCs) are a small part of the heterogeneous tumor cell population possessing self-renewal and multilineage differentiation potential as well…”
Get full text

Identification of a novel RNA aptamer that selectively targets breast cancer exosomes by Esposito, Carla Lucia, Quintavalle, Cristina, Ingenito, Francesco, Rotoli, Deborah, Roscigno, Giuseppina, Nuzzo, Silvia, Thomas, Renato, Catuogno, Silvia, de Franciscis, Vittorio, Condorelli, Gerolama

“…Breast cancer is a leading cause of cancer mortality in women. Despite advances in its management, the identification of new options for early-stage diagnosis…”
Get full text

miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment by Roscigno, Giuseppina, Cirella, Assunta, Affinito, Alessandra, Quintavalle, Cristina, Scognamiglio, Iolanda, Palma, Francesco, Ingenito, Francesco, Nuzzo, Silvia, De Micco, Francesca, Cuccuru, Antonio, Thomas, Renato, Condorelli, Gerolama

“…Breast cancer is the most frequent malignancy in females in terms of both incidence and mortality. Underlying the high mortality rate is the presence of cancer…”
Get full text

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial by Nuzzo, Francesco, Morabito, Alessandro, Gravina, Adriano, Di Rella, Francesca, Landi, Gabriella, Pacilio, Carmen, Labonia, Vincenzo, Rossi, Emanuela, De Maio, Ermelinda, Piccirillo, Maria Carmela, D'Aiuto, Giuseppe, Thomas, Renato, Rinaldo, Massimo, Botti, Gerardo, Di Bonito, Maurizio, Di Maio, Massimo, Gallo, Ciro, Perrone, Francesco, de Matteis, Andrea

“…To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or…”
Get full text

Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial by De Maio, Ermelinda, Pacilio, Carmen, Gravina, Adriano, Morabito, Alessandro, Di Rella, Francesca, Labonia, Vincenzo, Landi, Gabriella, Nuzzo, Francesco, Rossi, Emanuela, Silvestro, Pasqualina, Botti, Gerardo, Di Bonito, Maurizio, Curcio, Maria Pia, Formichelli, Franca, La Vecchia, Franca, Staiano, Maria, Maurea, Nicola, D'Aiuto, Giuseppe, D'Aiuto, Massimiliano, Thomas, Renato, Signoriello, Giuseppe, Perrone, Francesco, de Matteis, Andrea

“…After two studies reporting response rates higher than 70% in HER2-positive metastatic breast cancer with weekly trastuzumab and vinorelbine, we planned a…”
Get full text

Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer by Donnarumma, Elvira, Fiore, Danilo, Nappa, Martina, Roscigno, Giuseppina, Adamo, Assunta, Iaboni, Margherita, Russo, Valentina, Affinito, Alessandra, Puoti, Ilaria, Quintavalle, Cristina, Rienzo, Anna, Piscuoglio, Salvatore, Thomas, Renato, Condorelli, Gerolama

“…Cancer-associated fibroblasts (CAFs) are the major components of the tumor microenvironment. They may drive tumor progression, although the mechanisms involved…”
Get full text

Abstract 1170A: Organoids: A new tool for the prediction of breast cancer patients' outcome by Roscigno, Giuseppina, Cirella, Assunta, Affinito, Alessandra, Palma, Francesco, Albero, Maurizio, Messere, Martina, Gelormini, Martina, Cocca, Lorenza, Thomas, Renato, Condorelli, Gerolama

“…Abstract Breast cancer is one of the leading causes of cancer mortality among women. The main causes of death are related to recurrence and metastasis. One…”
Get full text

Abstract 5933: Cancer-associated fibroblasts (CAFs) release exosomal microRNAs that dictate an aggressive phenotype in breast cancer by Condorelli, Gerolama, Donnarumma, Elvira, Fiore, Danilo, Nappa, Martina, Roscigno, Giuseppina, Adamo, Assunta, Iaboni, Margherita, Russo, Valentina, Affinito, Alessandra, Quintavalle, Cristina, Rienzo, Anna, Piscuoglio, Salvatore, Thomas, Renato

“…Abstract Cancer-associated fibroblasts (CAFs), the major components of the tumor microenvironment may drive tumor progression. Exosomes mediate horizontal…”
Get full text

Radiofrequency ablation in patients with primary breast carcinoma : a pilot study in 26 patients by IZZO, Francesco, THOMAS, Renato, DELRIO, Paolo, RINALDO, Massimo, VALLONE, Paolo, DECHIARA, Anna, BOTTI, Gerardo, D'AIUTO, Giuseppe, CORTINO, Pina, CURLEY, Steven A

“…The authors performed a pilot trial of ultrasound-guided percutaneous radiofrequency ablation (RFA) in patients with T1 and T2 breast tumors 1) to confirm…”
Get full text

Primary phyllodes tumor of the axilla: DCE-MRI findings with 1.5T breast-dedicated system and pathological correlation by Petrillo, Antonella, Petrillo, Mario, Fulciniti, Franco, Raso, Mauro Mattace, Thomas, Renato, Botti, Gerardo, Siani, Alfredo

Get more information

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial by Nuzzo, Francesco, Morabito, Alessandro, De Maio, Ermelinda, Di Rella, Francesca, Gravina, Adriano, Labonia, Vincenzo, Landi, Gabriella, Pacilio, Carmen, Piccirillo, Maria Carmela, Rossi, Emanuela, D’Aiuto, Giuseppe, Thomas, Renato, Gori, Stefania, Colozza, Mariantonietta, De Placido, Sabino, Lauria, Rossella, Signoriello, Giuseppe, Gallo, Ciro, Perrone, Francesco, de Matteis, Andrea

“…Abstract Within an ongoing multicentre phase 3 randomised trial (ELDA, cancertrials.gov ID: NCT00331097 ), early breast cancer patients, 65–79 years old, with…”
Get full text

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients by Vecchio, S D, Ciarmiello, A, Potena, M I, Carriero, M V, Mainolfi, C, Botti, G, Thomas, R, Cerra, M, D'Aiuto, G, Tsuruo, T, Salvatore, M

“…Technetium-99m sestamibi is a transport substrate recognised by the multidrug-resistant P-glycoprotein (Pgp). To test whether 99mTc-sestamibi efflux is…”
Get full text

Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis by Iozzo, Renato V, Zoeller, Jason J, Nyström, Alexander

“…Proteoglycans located in basement membranes, the nanostructures underling epithelial and endothelial layers, are unique in several respects. They are usually…”
Get more information

Fractional Retention of Technetium-99m-Sestamibi as an Index of P-Glycoprotein Expression in Untreated Breast Cancer Patients by Del Vecchio, Silvana, Ciarmiello, Andrea, Pace, Leonardo, Potena, Maria I, Carriero, Maria V, Mainolfi, Ciro, Thomas, Renato, D'Aiuto, Giuseppe, Tsuruo, Takashi, Salvatore, Marco

“…The multidrug-resistant phenotype is characterized by the reduced intracellular retention of several structurally and functionally unrelated cytotoxic…”
Get full text

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study by FRASCI, Giuseppe, COMELLA, Pasquale, COMELLA, Giuseppe, THOMAS, Renato, DI BONITO, Maurizio, LAPENTA, Liliana, CAPASSO, Immacolata, BOTTI, Gerardo, VALLONE, Paolo, DE ROSA, Vincenzo, D'AIUTO, Giuseppe

“…Docetaxel (DTX) has been shown to be a very active drug in both breast cancer (BC) and non-small-cell lung cancer (NSCLC). Irinotecan (CPT-11) is also active…”
Get full text

Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients by Frasci, Giuseppe, D'Aiuto, Giuseppe, Thomas, Renato, Comella, Pasquale, Di Bonito, Maurizio, Lapenta, Liliana, D'Aiuto, Massimiliano, Botti, Gerardo, Vallone, Paolo, De Rosa, Vincenzo, D'Aniello, Roberta, Giordano, Renato, Comella, Giuseppe

“…To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with…”
Get more information

Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study by Frasci, Giuseppe, Comella, Pasquale, Thomas, Renato, Maurizio Di Bonito, Lapenta, Liliana, Capasso, Immacolata, Botti, Gerardo, Vallone, Paolo, De Rosa, Vincenzo, D'Aiuto, Giuseppe, Comella, Giuseppe

“…Docetaxel (DTX) has been shown to be a very active drug in both breast cancer (BC) and non-small-cell lung cancer (NSCLC). Irinotecan (CPT-11) is also active…”
Get full text

Radiofrequency ablation in patients with primary breast carcinoma by Izzo, Francesco, Thomas, Renato, Delrio, Paolo, Rinaldo, Massimo, Vallone, Paolo, DeChiara, Anna, Botti, Gerardo, D'Aiuto, Giuseppe, Cortino, Pina, Curley, Steven A.

“…BACKGROUND The authors performed a pilot trial of ultrasound‐guided percutaneous radiofrequency ablation (RFA) in patients with T1 and T2 breast tumors 1) to…”
Get full text

Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOQ) phase II study by FRASCI, Giuseppe, D'AIUTO, Giuseppe, D'ANIELLO, Roberta, FREZZA, Pasquale, LAPENTA, Liliana, COMELLA, Giuseppe, COMELLA, Pasquale, THOMAS, Renato, CAPASSO, Immacolata, DI BONITO, Maurizio, RIVELLINI, Flavia, CARTENI, Giacomo, DE LUCIA, Luigi, MAIORINO, Luigi

“…It has been shown in vitro that both cisplatin and epirubicin increase the antitumor activity of paclitaxel. Weekly administration could give a substantial…”
Get full text

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study by FRASCI, G, COMELLA, P, GRAVINA, A, MAIORINO, L, CARATENI, G, GENTILE, A, COMELLA, G, D'AIUTO, G, BUDILLON, A, BARBARULO, D, THOMAS, R, CAPASSO, I, CASARETTI, R, DAPONTE, A, CAPONIGRO, F

“…In a previous phase I study we found the MTDs of paclitaxel and cisplatin when given together weekly, with or without G-CSF support, in patients with advanced…”
Get full text